Dyadic International (DYAI) vs Jasper Therapeutics (JSPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dyadic International (DYAI) has outperformed Jasper Therapeutics (JSPR) over the past year, losing 60.7% versus a loss of 76.7%. Over five years, DYAI leads with a -90.8% price change compared with -99.7% for JSPR. Jasper Therapeutics is the larger company by market cap ($18.6 million vs $17.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYAI | JSPR |
|---|---|---|
| Share price | $0.4444 | $0.56 |
| Market cap | $17.80M | $18.63M |
| 1-day change | -2.65% | -1.70% |
| YTD return | -52.72% | -69.40% |
| 1-year return | -60.67% | -76.67% |
| 5-year return | -90.84% | -99.66% |
| EPS (TTM) | $-0.23 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.60 | $2.69 |
| 52-week low | $0.34 | $0.315 |
| Distance from 52-week high | -72.23% | -79.18% |
| Analyst consensus | none | none |
| Avg. price target upside | +1137.62% | +3471.43% |
| Average volume | 201.91K | 1.37M |
| Shares outstanding | 40.06M | 33.27M |
| Employees | 5 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYAI has outperformed JSPR by 16.0 percentage points over the past year.
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Healthcare · Biotechnology · 5 employees
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Healthcare · Biotechnology
DYAI vs JSPR FAQ
Which is bigger, Dyadic International or Jasper Therapeutics?
Jasper Therapeutics (JSPR) is larger, with a market capitalization of $18.63M compared with $17.80M for Dyadic International (DYAI).
Which stock has performed better over the past year, DYAI or JSPR?
DYAI returned -60.67% over the past 12 months, compared with -76.67% for JSPR (price return, excluding dividends). Past performance does not predict future results.
Are Dyadic International and Jasper Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.